Evaluation of the Efficacy and Safety of Different Duration of Proton Pump Inhibitor for Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery (DACAB-GI-2)

NCT03038009 Phase 4 WITHDRAWN

The purpose of this study is to determine whether 12-month prophylactic treatment with pantoprazole is superior to 1-month therapy without major cardiovascular events (MACE) increased significantly, in prevention of dual antiplatelet therapy (DAPT)-induced upper gastrointestinal (GI) mucosal injury after coronary artery bypass graft (CABG) surgery. The potentially serious harm of DAPT on gastroduodenal mucosa will be assessed by esophagogastroduodenoscopy (EGD).

Details

Lead sponsor	Ruijin Hospital
Phase	Phase 4
Status	WITHDRAWN
Start date	2018-10
Completion	2020-12

Conditions

• Gastric Ulcer Induced by Antiplatelet Agent
• Ulcer of the Gastrointestinal Tract
• Proton Pump Inhibitor

Interventions

• Pantoprazole

Primary outcomes

• Cumulative incidence of gastroduodenal erosions and ulcers. — up to 12 months

Countries

China